Skip to content
GLP-1 Desk
Menu

Head-to-head dispatch

HealthRX vs Signos

Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.

Dispatch #11Desk pick
HealthRX

A LegitScript-certified compounding platform whose pricing page prints every plan's total, per-month rate and renewal price — and whose renewals are cheaper than sign-up.

$190/mo month-to-month ($149 first month on Subscribe & Save, renews at $165) · $99/mo on a 12-month prepay ($1,188) sema · $239/mo month-to-month ($193 first month on Subscribe & Save, renews at $214) · $179/mo on a 12-month prepay ($2,148) tirz · Verified August 29, 2026

Marked down on: Compounded medications are not FDA-approved

vs
Dispatch #288
Signos

Signos (Signos+) is a metabolic-health platform that bundles clinician-prescribed compounded GLP-1 (semaglutide) with an FDA-cleared continuous glucose monitor (CGM) and app.

$199/mo (6-month plan, compounded) sema · $199/mo (starting dose, compounded) tirz · Verified July 25, 2026

Marked down on: Compounded GLP-1s are not FDA-approved finished products

HealthRX takes this head-to-head with the higher Desk Score, 86/100 (B) against 62/100 (C) for Signos. Signos still holds its ground where its strengths line up with yours.

Desk Score, dimension by dimension

Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.

HealthRX

86/100

B

Overall

Signos

62/100

C

Price transparency

82
68

State access

80
24

Molecule range

94
66

Onboarding speed

84
72

Support responsiveness

82
82

Licensing & trust

90
78

The spec sheet

FieldHealthRXSignos
Semaglutide$190/mo month-to-month ($149 first month on Subscribe & Save, renews at $165) · $99/mo on a 12-month prepay ($1,188)$199/mo (6-month plan, compounded)
Tirzepatide$239/mo month-to-month ($193 first month on Subscribe & Save, renews at $214) · $179/mo on a 12-month prepay ($2,148)$199/mo (starting dose, compounded)
CoverageAll 50 statesNot listed on Signos's site (checked July 25, 2026)
Brand-nameCompounded onlyCompounded only
Oral optionInjectable onlyInjectable only
Best forPatients who want a certified program with every plan price and renewal in one table, and a full refund if a provider does not approve them.Pairing compounded GLP-1 (semaglutide) with an FDA-cleared continuous glucose monitor and app.
Desk Score86/100B62/100C

The verdict

Desk pick — HealthRX

HealthRX takes this head-to-head with the higher Desk Score, 86/100 (B) against 62/100 (C) for Signos. Signos still holds its ground where its strengths line up with yours.

Choose HealthRX if…

Patients who want a certified program with every plan price and renewal in one table, and a full refund if a provider does not approve them.

$190/mo month-to-month ($149 first month on Subscribe & Save, renews at $165) · $99/mo on a 12-month prepay ($1,188) sema · $239/mo month-to-month ($193 first month on Subscribe & Save, renews at $214) · $179/mo on a 12-month prepay ($2,148) tirz · All 50 states

Choose Signos if…

Pairing compounded GLP-1 (semaglutide) with an FDA-cleared continuous glucose monitor and app.

$199/mo (6-month plan, compounded) sema · $199/mo (starting dose, compounded) tirz

Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way. Read full breakdowns: HealthRX · Signos.

Also here

CoreAge Rx tops every dispatch at 94/100

Whichever of these two you lean toward, the Desk's #1-rated provider outscores them both. The Desk's top dispatch: one price at every dose, both molecules, all 50 states — but the $99 and $149 figures are 12-month plans paid up front, not a monthly bill.

More head-to-heads

Or see the full comparison hub and the complete ranking.

Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.